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New biological activities of bone morphogenetic proteins (BMPs) in the endocrine system have recently 
been revealed.  The BMP system is composed of approximately 30 ligands and preferential combina-
tions of type I and type II receptors.  The BMP system not only induces bone formation but also plays 
unique tissue-speciﬁc roles in various organs.  For instance,  the ovarian BMP system is a physiological 
inhibitor of luteinization in growing ovarian follicles.  In the ovary,  the expression of oocyte-derived 
BMP-15 is critical for female reproduction.  In the pituitary,  BMP-4 is a key player for initial develop-
ment of the anterior pituitary,  while it is also functionally involved in some diﬀerentiated pituitary 
tumors,  including prolactinoma and Cushingʼs disease.  In the adrenal glands,  BMP-6 and BMP-4 
modulate aldosterone and catecholamine production,  respectively,  which contributes to a functional 
interaction between the cortex and medulla.  In the present review,  recent advances in BMP biology in 
the ﬁeld of endocrinology are described and the possibility for clinical application of BMP activity is 
discussed.
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one morphogenetic proteins (BMPs) were iden-
tiﬁed by Urist [1] as active components in 
demineralized bone and bone extracts that are capable 
of inducing bone formation at ectopic sites [2].  
Thereafter,  a number of new BMP family genes were 
identiﬁed using homology-based cloning.  Based on the 
structure of amino acid sequences from the corre-
sponding cDNAs,  BMP ligands are classiﬁed into 
transforming growth factor (TGF)-β superfamily 
members.
　 To date,  more than 30 members of the TGF-β 
superfamily have been identiﬁed in various species [3,  
4].  Not all of the BMP family members induce bone 
formation or diﬀerentiation,  though all BMPs con-
tribute to the regulation of multiple biological pro-
cesses,  including cell proliferation,  apoptosis,  dif-
ferentiation and morphogenesis in various tissues in 
the body [5].  For instance,  in contrast to BMP 
ligands that can elicit bone-forming eﬀects,  such as 
BMP-2,  -4,  -6 and -7,  BMP-3b inhibits the process 
of osteoblast diﬀerentiation and antagonizes the 
actions of BMP-2 [6].
　 Accumulating evidence has led to the concept that 
BMPs formulate a multifunctional regulator system in 
various biological processes in vertebrates as well as 
invertebrates [7].  In addition to their expression in 
bone,  BMPs are expressed in the kidney (BMP-3,  -4 
and -7),  lung (BMP-3,  -4,  -5 and -6),  small intestine 
(BMP-3 and -7),  heart (BMP-2,  -4,  -6 and -7),  limb 
bud (BMP-2,  -4,  -5 and -7) and teeth (BMP-3,  -4 and 
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-7),  in which they regulate cellular homeostasis by an 
autocrine/paracrine mechanism [8-11].  Recent stud-
ies have shown that the BMP system is a critical 
component of the local regulatory system in endocrine 
tissues.  Various BMP actions have been observed in 
numerous tissues,  including the ovary,  pituitary and 
adrenal glands [12],  and new regulatory roles of 
BMPs in bone formation and/or bone diﬀerentiation 
have also been shown [13-16].
　 Seven type-I (activin receptor-like kinase (ALK)-1 
to -7) and 5 type II (activin type II receptors (ActRII/
IIB),  anti-Müllerian hormone receptor (AMHR)-II,  
BMP type II receptor (BMPRII) and TGF-β type II 
receptor (TβRII)) receptors for TGF-β superfamily 
members have been characterized in mammals.  Type 
I and type II receptors are structurally similar and 
both types possess Ser/Thr-kinase domains in intrac-
ellular regions.  Type I receptors have a Gly/Ser-rich 
GS domain in the trans-membrane region.  Although 
TGF-β and activin initially bind to type II receptors 
and type I receptors are subsequently recruited into 
the complex,  type II as well as type I receptors inde-
pendently have certain aﬃnity for BMP ligands and the 
type I/II complex can achieve higher aﬃnity binding 
[17].
　 The pathway-restricted Smads (called R-Smads),  
Smad1/5/8,  are activated following the binding of 
BMP ligands to the receptors.  They interact with a 
common-mediator Smad (Co-Smad),  Smad4,  to form a 
complex,  which is then translocated into the nucleus 
for binding to target DNA and the induction of speciﬁc 
gene transcription [18].  Two inhibitory Smads 
(I-Smads),  Smad6/7,  act in competition with Smad4 
and regulate the target-gene transcription of BMP 
signaling.  Alternative signaling pathways such as 
TGF-β-activated kinase (TAK-1),  a member of the 
mitogen-activated protein kinase kinase kinase 
(MAPKKK) family,  and members of the Ras/Rac 
families of small GTP-binding proteins can also be 
activated.  Depending on cell types,  extracellular 
signal-regulated kinase-1/2 (ERK1/2) and stress-
activated protein kinase (SAPK)/Jun-N-terminal 
kinase (JNK) may be involved in TGF-β signal trans-
duction.
Reproductive Roles of the BMP System
　 Oocyte-derived factors have recently proven to be 
of critical importance to ovarian function and female 
reproductive biology.  This is based on the concept of 
mutual communication of oocytes and surrounding 
somatic cells that is critical for normal follicular 
development [19,  20].  Folliculogenesis is regulated 
by the actions of oocytes,  wherein oocyte-derived 
growth factors act on neighboring follicular cells and 
integrate various functions of granulosa cells.  Local 
factors expressed in the ovary,  including BMPs,  
growth and diﬀerentiation factors (GDFs),  activins 
and inhibins play various autocrine/paracrine roles in 
female fertility by regulating steroidogenesis as well 
as mitogenesis in granulosa cells [21-23] (Fig.  1).  
Expression of mRNA and/or protein for the BMP 
system components,  including ligands,  receptors and 
intracellular signal transduction factors,  has been 
demonstrated in the cells of growing follicles [24,  
25].  The biofunctional activity of BMPs in the regu-
lation of ovarian function has been gradually eluci-
dated [22,  26,  27].
　 The ﬁnding that defects of the oocyte-speciﬁc 
growth factors GDF-9 and BMP-15 cause female 
infertility was an important breakthrough in this ﬁeld 
[28,  29].  BMP-15 is exclusively expressed in oocytes 
[30] and has been shown to induce granulosa cell 
mitosis and inhibit the actions of FSH by suppressing 
follicle-stimulating hormone (FSH) receptor (FSH-R) 
expression [31].  The spontaneously-occurring infer-
tile strain of Inverdale sheep was found to carry a 
single point mutation in the mature-protein region of 
the bmp15 gene [29].  In the heterozygotes of Inverdale 
mutants,  reduced BMP-15 causes higher expression 
of FSH-R in granulosa cells,  leading to more develop-
ing follicles and higher expression of luteinizing hor-
mone (LH) receptors (LH-R).  The heterozygous mutants 
therefore exhibit increased ovulation rates,  resulting 
in increased twinning.  The aberrant reproductive 
biology of heterologous mutant Inverdale sheep appears 
to be based on precocious maturation of follicles and 
the resultant increased numbers of ovulatory follicles.  
On the other hand,  homozygous Inverdale female sheep 
are infertile due to arrested follicle development at the 
primary follicle stage.  The lack of bioactive BMP-15 
and its mitotic eﬀects lead to arrest of follicle devel-
opment in homozygotes of the Inverdale strain [30].
　 Some individuals of another sheep strain,  the 
highly proliﬁc strain Booroola,  were found to carry a 
mutation in the ALK-6 (BMPRIB) receptor [32-34],  
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which is a key receptor for BMP-15.  Ovarian follicles 
of Booroola sheep produce more progesterone in 
response to FSH than do those of the wild type [35].  
BMP-15 signaling is mediated by binding ﬁrst to 
ALK-6 and then recruiting BMPRII to the complex 
[36].  The enhanced FSH responsiveness of the folli-
cles from Booroola ewes has been proposed to be due 
to impaired ALK-6 signaling elicited by endogenous 
BMP-15 and/or BMP-6 [21].  Thus,  the reproduc-
tive phenotypes of sheep coupled with evidence from 
in vitro ﬁndings have established roles of BMP-15 
signaling in the regulation of follicular development 
and also shown the importance of oocyte-secreted fac-
tors in the ﬁeld of mammalian reproduction.
　 BMP-2,  -4,  -6 and -7 also exert unique eﬀects on 
ovarian steroidogenesis and granulosa cell mitosis in 
the ovary (Fig.  1).  BMP-6 (expressed in oocytes and 
granulosa cells of healthy Graaﬁan follicles [24]) 
inhibits the actions of FSH by suppressing adenylate 
cyclase activity [37],  leading to the process of domi-
nant follicle “selection. ” BMP-4 and -7 (expressed in 
theca cells) increase FSH-induced estradiol production 
and suppress progesterone production [38].  BMP-7 
promotes the “recruitment” process of primordial fol-
licles into the growing follicle pool [39].  The actions 
of BMP-7 on FSH-induced estradiol production occur 
through suppression of ERK1/2 downstream of FSH 
receptor signaling [40].  BMP-2 and -4 stimulate 
FSH-induced p38-MAPK phosphorylation,  leading to 
an increase of FSH-induced estradiol production [41].  
In addition,  some of the BMP actions are extracellu-
larly regulated by the binding protein follistatin [42],  
while BMP-Smad signal activities are also regulated 
by FSH receptor signaling,  leading to ﬁne-tuning of 
the mutual sensitivities of BMPs and FSH [43].  
Thus,  each BMP ligand diﬀerentially regulates FSH-
induced steroidogenesis by granulosa cells by a ligand-
dependent mechanism,  but the BMP ligands commonly 
work as “luteinization inhibitors” [21].
　 BMP-15 also stimulates granulosa cell prolifera-
77BMP System as an Endocrine RegulatorApril 2013
Aromatase
granulosa cell
Estrogen
StAR, P450scc,
3βHSD
oocyte
BMP-4
BMP-7
BMP-6
BMP-15
BMP-2
BMP-15
GDF-9
FGF-8
BMP-6
BMP-15
GDF-9
FGF-8
theca cell
Progesterone
Kit ligand
Kit ligand
mitosis
c-kit
Steroidogenesis
DNA synthesis
Cell proliferation
MAPK
FSH
FSH
R
p38
ERK JNK
cAM
P
PKA
Fig. 1　 Reproductive roles of the BMP system in the ovary.  FSH activates estradiol and progesterone production through the cAMP-to-
PKA pathway in granulosa cells in the ovary.  FSH simultaneously stimulates MAPKs,  including the ERK and p38 pathways,  leading to 
pathway-speciﬁc modulation of FSH-induced steroidogenesis.  Oocyte-derived BMP-15 inhibits FSH receptor (FSH-R) expression,  while 
BMP-6 suppresses cAMP synthesis,  both of which lead to reduction of progesterone production.  BMP-2 and -4 activate FSH-induced p38,  
leading to stimulation of estradiol production.  BMP-7 inhibits FSH-induced ERK1/2 phosphorylation,  leading to activation of estradiol 
production.  Oocytes and/or oocyte-derived factors also facilitate FSH-to-MAPKs and BMP-to-Smad signaling activity through oocyte-
granulosa cell communication.  Oocyte-secreted BMP-15 stimulates granulosa cell mitosis with Kit ligand (KL) expression.  KL acts through 
c-kit on the surface of oocytes to inhibit BMP-15 expression,  forming a negative feedback loop.  KL-to-c-kit signaling not only increases 
granulosa cell mitosis but also aﬀects the expression of oocyte factors such as BMPs and FGF-8,  leading to the maintenance of steroido-
genesis.
tion in a dose-dependent manner [30] via kit ligand 
(KL)-c-kit interaction between oocytes and granulosa 
cells [44] (Fig.  1).  In addition to the oocyte-to-somatic 
cell communication,  the physiological importance of 
granulosa-to-oocyte signaling was recognized in natu-
rally occurring mutations at the loci of c-kit and KL in 
mice,  resulting in developmental abnormalities in 
oogenesis and folliculogenesis [45,  46].  The KL 
receptor c-kit mRNA/protein is localized to oocytes 
during postnatal ovarian development,  while KL 
mRNA expression is localized to granulosa cells in the 
follicles [45].  Thus,  it is possible that KL action 
contributes to the communication from granulosa cells 
to oocytes via c-kit signaling [46,  47].  The functional 
interaction of the granulosa-derived KL and oocyte 
c-kit is also indispensable for normal fertility.  Inter-
estingly,  BMP-15 and KL are concomitantly expressed 
in the early stages of follicular development and 
appear to be involved in granulosa cell mitosis [44] by 
forming a negative feedback loop between the oocyte 
and surrounding granulosa cells.  The combination of 
increased KL expression and subsequent reduction of 
BMP-15 expression contribute to an eﬀective and 
balanced induction of granulosa cell proliferation [44].
　 KL-c-kit interaction is not only involved in oocyte 
maturation and mitotic regulation of granulosa cells 
but also plays a role in estrogenic regulation through 
oocyte-granulosa communication (Fig.  1).  This bidi-
rectional communication between oocytes and granu-
losa cells involves oocyte-derived growth factors,  
including ﬁbroblast growth factor (FGF)-8 and BMP-
15/GDF-9,  leading to control of the FSH-induced 
estrogenic capability of granulosa cells.  Oocyte-
derived BMP-15 stimulates KL expression in rat 
granulosa cells,  leading to stimulation of granulosa 
cell proliferation [44],  while GDF-9 suppresses KL 
expression in mouse granulosa cells [48].  Therefore,  
it has been hypothesized that the KL-c-kit interaction 
plays a regulatory role not only in the early process of 
mitogenesis but also in steroidogenesis by granulosa 
cells,  which is further controlled by oocyte factors.  It 
was recently found that KL-c-kit interactions sup-
pressed FSH-induced estradiol production and aro-
matase mRNA expression without aﬀecting FSH-
induced progesterone production by granulosa cells in 
the presence of oocytes [49].
　 The intracellular interaction between BMP-15 and 
GDF-9 is also an interesting issue with regard to the 
secretion of active mature proteins.  BMP-15 and 
GDF-9 diﬀer from other TGF-β members in that their 
mature regions lack the 7th Cys residue that is 
responsible for intra-molecular bonding [50,  51].  It 
is therefore reasonable to expect that BMP-15 and 
GDF-9 form heterodimers [52,  53].  Posttransla-
tional modiﬁcation by phosphorylation is also critical 
for bioactivity of BMP-15 and GDF-9,  and the 
dephosphorylated forms of BMP-15 and GDF-9 
exhibit antagonistic activity to the phosphorylated 
normal ligands [54].  Moreover,  FGF-8,  another 
oocyte-derived factor,  is associated with the regula-
tion of BMP activity.  FGF-8 suppresses FSH-induced 
estrogen production but ampliﬁes BMP signaling 
through oocyte-granulosa cell communication [55].  
The interaction between FGF and BMP systems is 
critical for the maintenance of FGF receptor signaling 
itself in granulosa cells [56].  The interaction between 
FGF-8 and BMP-15/GDF-9 signaling could be a key 
for understanding the regulation of FSH-induced 
estrogen production through oocyte-granulosa cell 
communication via KL-c-kit interaction.
BMP Action in Pituitary Tumors
　 In the pituitary,  the BMP system plays important 
roles in development of the anterior pituitary [57].  
BMP-4 is required during the initial process of pitu-
itary organogenesis for forming Rathkeʼs pouch,  and 
inhibition of BMP-2 by FGF-8 in turn facilitates the 
diﬀerentiation of corticotrope cells [58,  59].  Suga et 
al.  recently reported exciting data showing a role of 
BMP-4 in the eﬃcient self-formation of three-dimen-
sional adenohypophysis in an aggregate culture of 
mouse embryonic stem (ES) cells [60].  A large cell-
aggregation culture of mouse ES cells was success-
fully induced for diﬀerentiation into anterior pituitary 
tissues.  In this process,  BMP-4-treated ES cells 
increased expression of the Rathkeʼs marker Pitx2 but 
inhibited the formation of hypothalamic tissues.  Since 
a BMP antagonist inhibited the induction of Rathke,  
an endogenous BMP signal was shown to be critical for 
development of the anterior pituitary.
　 Recent studies have further revealed a new role of 
BMP-4 in the pathogenesis of the diﬀerentiated ante-
rior pituitary [61,  62] (Fig.  2).  The BMP-4 molecule 
was found to be overexpressed in lactotrope adenomas 
derived from dopamine D2 receptor null mice and 
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estrogen-treated female rat pituitary tissues.  Increased 
BMP-4 expression was also detected in human prolac-
tinomas compared with its expression levels in other 
functioning and nonfunctioning tumor tissues [63].  
Biologically,  BMP-4 promotes not only lactotrope cell 
proliferation [63] but also prolactin production in 
conjunction with Smad-estrogen receptor (ER) inter-
action [64].  The crosstalk between BMP-4 and 
estradiol occurs both at the level of prolactin secre-
tion and at the level of its promoter activation [64].  
BMP-4 inhibits the transcriptional activity of ER,  
while estrogen stimulates the transcriptional activity 
of BMP-4-speciﬁc Smad signaling.  Given that the 
expression of a BMP antagonist,  noggin,  is down-
regulated in a prolactinoma mouse model [63],  
endogenous BMP-4 should be involved in growth pro-
motion and prolactin productivity by lactotropes 
through the Smad-ER interaction.
　 Furthermore,  we recently found a functional inter-
relationship between the BMP system and somatosta-
tin receptor (SSTR) expression in relation to growth 
hormone (GH) and prolactin secretion [65,  66] (Fig.  
2).  Somatostatin acts by binding to 5 subtypes of G 
protein‒coupled receptors that are widely distributed 
in many endocrine and nonendocrine tissues.  The 
eﬃcacy of somatostatin analogs is linked to the SSTR 
selectivity proﬁle,  in which binding to SSTR2 and 
SSTR5 is critical for proper function [67].  SSTR2 
and SSTR5 are negatively coupled to adenylyl cyclase,  
the activation of which results in a reduction of intra-
cellular cAMP levels [68].  A unique action of the 
pituitary BMP system in the modulation of prolactin 
secretion regulated by somatostatin analogs was 
uncovered in lactosomatotrope GH3 cells expressing 
SSTRs.  Importantly,  BMP-4 reduced SSTR2 
expression but increased SSTR5 expression [69].  
The eﬀect of the SSTR5-preferring agonist pasire-
otide,  which reduced the prolactin secretion induced 
by forskolin,  was facilitated by the presence of BMP-4 
and,  in turn,  blocked by noggin treatment.  Thus,  
BMP-4 acts to increase prolactin release and,  fur-
thermore,  the BMP system plays a regulatory role in 
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Fig. 2　 Roles of the BMP system in pituitary tumors.  In lactosomatotrope cells,  BMP-4 stimulates the cAMP-PKA pathway via 
Smad1/5/8 signaling,  leading to enhancement of PRL (and/or GH) production.  BMP activity is also involved in modulation of SSTR sen-
sitivity in lactosomatotrope cells,  in which BMP-4 augments SSTR5 expression but suppresses SSTR2 expression.  In corticotrope cells,  
BMP-4 suppresses CRH-induced MAPK (ERK1/ERK2 and p38-MAPK) activity and POMC transcription via Smad1/5/8 signaling,  leading 
to reduction of ACTH production.  The BMP response is upregulated by SSTR analogs through SSTR5 and,  to a lesser extent,  through 
SSTR2.  GH-releasing peptide (GHRP) also activates POMC transcription and ACTH production in corticotrope cells,  although the eﬀect is 
much less potent than that of CRH.
the SSTR sensitivity of lactotrope tumor cells [69].
　 Prolactinomas are the most frequently occurring 
human functioning pituitary tumors.  Administration of 
dopamine agonists (DA) is the major choice for treat-
ment of general prolactinomas [70].  DA administra-
tion suppresses prolactin secretion and cell prolifera-
tion by interacting with D2 receptors [71].  D2R 
agonists are eﬃcient in the majority of cases.  However,  
some cases of prolactinomas fail to attain PRL nor-
malization and reduction in tumor size even with the 
most potent dopamine agonist,  cabergoline [72-74].  
In such tumors that are poorly or partially responsive 
to DA,  an alternative medical treatment is needed.  
Among SSTRs expressed in prolactinomas,  SSTR5,  
but not SSTR2,  is predominantly detected [75].  
This expression pattern indicates that established 
somatostatin analogs such as octreotide and lanreotide 
(SSTR2-preferring agonists) are much less eﬀective 
for suppressing prolactin secretion from prolactino-
mas compared with pasireotide (an SSTR5/2-prefer-
ing agonist) [76].
　 An interaction between the BMP-Smad pathway 
and corticotropin-releasing hormone (CRH) receptor 
signaling is involved in controlling ACTH production 
by corticotrope cells in an autocrine/paracrine man-
ner [77,  78] (Fig.  2).  In cases of corticotrope tumors,  
BMP ligands,  particularly BMP-4,  potentially sup-
press ACTH production by inhibiting CRH-induced 
MAPK pathways.  In mouse corticotropinoma model 
AtT20 cells,  it was found that somatostatin analogs 
upregulated BMP-Smad1/5/8 activity,  increased the 
expression of ALK-3/BMPRII and downregulated 
inhibitory Smad6/7 molecules [77].  Thus,  activation 
of the endogenous BMP system is likely to be involved 
in the mechanism by which somatostatin analogs sup-
press CRH-induced ACTH production [77].  Neither 
BMP-4 nor a somatostatin analog elicited signiﬁcant 
suppression of AtT20 cell proliferation.  Nevertheless,  
it was notable that BMP-4 showed a signiﬁcant inhibi-
tion of cell mitosis in the presence of somatostatin 
analogs [77].  These ﬁndings suggest that somatosta-
tin analogs facilitate the actions and/or signal trans-
duction of BMP-4.
　 SSTR2 is known to be downregulated by excess 
glucocorticoids,  and the inhibition of SSTR2 expres-
sion by excess cortisol may cause the ineﬀectiveness 
of the SSTR2-preferring analog,  octreotide,  in patients 
with pituitary corticotropinomas SSTR2 expression 
upregulated by TGF-β in corticotrope cells via Smad4 
activation [79].  Overexpression of Smad4 restores 
SSTR2 expression and reverses the growth inhibition 
elicited by somatostatin.  These ﬁndings suggest that 
Smad4 is associated with the expression and function 
of SSTR2 in pituitary tumors [79].  Although the 
direct eﬀects of BMPs on the SSTR expression pro-
ﬁle have yet to be elucidated,  SSTR action is sub-
stantially involved in the bioactivity of endogenous 
BMP responsiveness leading to ACTH reduction 
[77].  Considering that somatostatin analogs enhanced 
BMP-Smad1/5/8 signal intensity in corticotrope cells,  
activation of the endogenous BMP system may be 
crucial for the mechanism by which pasireotide and/or 
octreotide suppress CRH-induced ACTH production 
in Cushingʼs tumors.
BMPs in the Adrenal System
　 Regulation of adrenal function is important for the 
control of hypertension and its associated organ dam-
age.  A functional BMP and activin system complete 
with ligands including BMP-6 and activin βA/βB,  the 
receptors ALK-2,  ALK-3,  ALK-4,  ActRII and 
BMPRII,  and the binding protein follistatin exists in 
human adrenocortical cells [80] (Fig.  3).  Activin and 
BMP-6 cause concentration-dependent increases in 
aldosterone production with increased expression of 
StAR,  P450scc and CYP11B2.  Activin regulates 
aldosterone synthesis predominantly by modulating the 
ACTH-cAMP-PKA signaling pathway [81].  On the 
other hand,  BMP-6 contributes to angiotensin II (Ang 
II)-induced aldosterone production by activating 
Smad1/5/8 after binding to ALK-2/3 in combination 
with ActRII [82].
　 Aldosterone production stimulated by Ang II in 
human adrenocortical cells was blocked by an Ang II 
type 1 receptor (AT1R) blocker (ARB) in a concen-
tration-dependent manner [83].  However,  the sup-
pressive eﬀects of the ARB on Ang II-induced aldos-
terone production and CYP11B2 expression were 
impaired during a chronic course of ARB treatment 
for approximately 2 weeks.  Expression of BMP-6 and 
its receptors,  including ALK-2 and ActRII,  was 
decreased by chronic Ang II exposure.  This decrease 
in expression was reversed by co-treatment with ARB 
in adrenocortical cells.  Given that in vitro break-
through is attenuated by the neutralization of endog-
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enous BMP-6 and ALK-2,  the bioavailability of 
BMP-6 in the adrenal cortex is likely to be involved in 
the occurrence of cellular escape from aldosterone 
suppression under chronic treatment with an ARB.
　 The physiological role of BMP-6 in regulation of 
aldosterone in vivo was also examined by utilizing rats 
treated with immunization against BMP-6 [84].  
Reduction of urinary aldosterone excretion was caused 
by BMP-6 inhibition,  suggesting that endogenous 
BMP-6 contributes to the induction of aldosterone 
production in vivo.  In contrast,  with Ang II treatment,  
urinary aldosterone and the creatinine-corrected val-
ues were not diﬀerent between the 2 groups,  suggest-
ing that BMP-6 activity was impaired under the condi-
tion of chronic treatment with Ang II.  This phenomenon 
is the same as that demonstrated in our previous in 
vitro study [83].  The reduction of CYP11B2 mRNA 
and reduction of the ratio of plasma aldosterone/cor-
ticosterone by treatment with BMP-6 immunization 
further suggested a selective role of BMP-6 in aldos-
terone production by the zona glomerulosa of the 
adrenal cortex.  Collectively,  these ﬁndings indicate 
that BMP-6 is likely to act as one of the modulatory 
factors in aldosterone production to maintain systemic 
aldosterone levels.
　 The adrenal cortex and medulla functionally inter-
act with each other in an autocrine/paracrine manner 
[85,  86] (Fig.  3).  Endogenous glucocorticoids are 
known to induce catecholamine biosynthesis by stimu-
lating catecholamine-synthesizing enzymes through the 
cortico-medullary portal system [87].  The presence 
of the BMP system in the adrenal medulla and func-
tional crosstalk between glucocorticoid and the BMP 
system in regulating catecholamine synthesis were 
found in adrenomedullar cells [88].  The key compo-
nents of the BMP system are expressed throughout 
neural development [89].  For instance,  BMP-4 and 
BMP-7 are expressed in the dorsal aorta and direct 
sympathetic neuronal diﬀerentiation into the adrener-
gic characteristics [90].  BMP-4 and BMP-7 induce a 
tyrosine hydroxylase (TH)-immunoreactive adrenergic 
phenotype in cultures of avian neural crest cells [91,  
92].  We also found that BMP-4 induces cate-
cholamine production in the presence of mineralocor-
ticoid in adrenomedullar PC12 cells.  Catecholamine 
biosynthesis in adrenomedullar cells occurs via the 
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Fig. 3　 Roles of the BMP system in the adrenal cortex.  In the adrenal cortex,  BMP-6 contributes to Ang II-induced aldosterone produc-
tion by activating Smad1/5/8,  which preserves Ang II-induced ERK activation.  On the other hand,  aldosterone production induced by 
activin is likely to be regulated via mechanisms that enhance the authentic steroidogenic pathway of ACTH-cAMP-PKA.  In the adrenal 
medulla,  aldosterone secreted from the adrenal cortex stimulates catecholamine production and tyrosine hydroxylase (TH) expression by 
genomic and non-genomic actions through MR-dependent and MR-independent SAPK/JNK signaling.  BMP-4 enhances aldosterone-
induced catecholamine production and TH mRNA expression via MR by upregulating non-genomic actions through Rho-SAPK/JNK path-
ways.  Adrenal BMPs are important for the interaction between the adrenal cortex and medullar function.
mineralocorticoid receptor (MR) through genomic 
action and partly through non-genomic action by Rho-
SAPK/JNK signaling [93]; as well as by glucocorti-
coid action via glucocorticoid receptor (GCR).  Given 
that the non-genomic pathway was activated by BMP-
4,  this adrenocortical-medullar interaction via MR and 
BMPs was hypothesized to be involved in cate-
cholamine regulation [93].
Perspective on Clinical Application of BMPs
　 Various BMP actions in endocrine tissues,  includ-
ing ovary,  pituitary,  thyroid,  adrenal and cardiovas-
cular tissues,  have been gradually discovered.  As for 
ovarian BMPs,  it is exciting that a point mutation in 
the bmp15 gene has been discovered in infertile women 
with hypergonadotropic ovarian failure [94].  Recom-
binant proteins with this mutation lack biological 
activity but exert antagonistic eﬀects on normal BMP-
15 activity.  Further studies revealed that several 
mutations in the bmp15 and gdf9 genes localized at the 
pro-protein coding region were involved in premature 
ovarian failure (POF) [95-97].  POF is a common 
cause of infertility in women,  which can manifest as 
primary amenorrhea or secondary amenorrhea after 
pubertal development.  POF is caused by follicle dys-
function and/or depletion,  the latter of which is due 
to accelerated recruitment or increased atresia.  Since 
BMP-15 and GDF-9 play a role both in promoting 
early follicle growth and restraining dominant/preo-
vulatory follicle development,  supplementation of 
BMP-15 and GDF-9 may overcome the follicle dys-
function or depletion shown in POF.  Further work 
remains to be done to tie these ﬁndings together and 
develop a deeper understanding of the BMP-15 and 
GDF-9 interaction in female reproduction.
　 The importance of ovarian BMPs was also found in 
granulosa cell models exposed to high levels of GH and 
prolactin.  Based on our recent ﬁndings,  it is likely 
that endogenous BMPs play roles in inhibiting and/or 
neutralizing GH/insulin-like growth factor (IGF)-I 
eﬀects on FSH-induced steroidogenesis in granulosa 
cells [98].  The suppression by BMP of FSH-induced 
progesterone synthesis was disturbed by treatments 
with GH and/or IGF-I.  IGF-I in turn showed antago-
nistic eﬀects on FSH-induced progesterone suppres-
sion by BMP-2,  -4,  -6,  -7 and -15.  Balanced intensi-
ties between the GH-IGF-I axis and BMP system may 
be physiologically critical for regulating gonadotro-
pin-induced steroidogenesis in growing follicles.  In the 
case of the prolactin excess observed in prolactinoma 
patients,  prolactin suppresses FSH-induced estradiol 
production by augmenting FSH-induced MAPK activ-
ity with prolactin receptor up-regulation [99].  
Prolactin enhances the expression of endogenous 
BMP-Smad1/5/8 signaling activity via the JAK/
STAT pathway,  whereas BMPs suppress prolactin 
receptor expression in granulosa cells.  Hence,  the 
BMP system in growing follicles plays a role in help-
ing the ovary to withstand exposure to high concentra-
tions of GH and/or prolactin.
　 In the pituitary,  BMP-4 seems to act as a func-
tional modulator for various agents such as soma-
tostatin and dopamine in an autocrine/paracrine man-
ner,  leading to ﬁne-tuning of the sensitivity in 
lactotropes and corticotropes.  For treatment of pitu-
itary adenomas that have recurred after surgery and/
or medication-resistant adenomas,  alternative thera-
peutic strategies are clinically required [100].  The 
currently available medication for corticotropinomas 
is,  in general,  less eﬀective for controlling cases that 
have recurred and/or residual tumors after surgery.  
As for prolactinomas,  cases with low sensitivity to DA 
occasionally exist.  In addition to the use of soma-
tostatin analogs for acromegaly patients,  somatostatin 
analogs may also have potential as a therapeutic agent 
for resistant cases of other functioning tumors.  The 
functional link between BMP-Smad signaling and 
SSTR actions may be involved in individual tolerance 
to somatostatin analogs for various pituitary ade-
nomas.  Elucidation of the changes in expression of 
BMP-4,  BMP receptors and SSTRs in functioning 
pituitary tumors would provide a clue for clarifying 
this interrelationship.
　 In terms of the adrenal BMP system,  BMP-6 
activity may be one of the causes of aldosterone 
breakthrough or the escape phenomenon observed in 
hypertensive patients treated with long-term ACE 
inhibitor and/or ARB therapy.  Various factors,  such 
as ACTH,  electrolytes,  endothelins and Ang II type 
2 receptor actions,  have been proposed as the cause 
of aldosterone breakthrough.  Among these,  the renin-
angiotensin-aldosterone (RAA) system is still a key 
regulator of blood pressure and ﬂuid homeostasis.  
The breakthrough phenomenon might be associated 
with important cardiovascular and renal outcomes.  It 
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is therefore important to elucidate the molecular cause 
of aldosterone breakthrough.  Changes in the bioavail-
ability of BMP-6 and cellular BMP responsiveness 
are,  at least in part,  involved in the occurrence of 
cellular escape from aldosterone suppression under the 
condition of chronic AT1 blockade.  Further approaches 
are necessary to determine the factors that control 
BMP-6 expression in the adrenal and pathophysiologi-
cal roles of the adrenocortical BMP-6 in aldosterone 
breakthrough.
Conclusion
　 It has gradually been found that the BMP system 
is a ﬁne regulator of fundamental endocrine activity at 
various levels.  Accordingly,  further research in this 
ﬁeld will greatly expand our understanding regarding 
the pathophysiology of classical endocrine regulation 
modulated by local BMP signaling.  Future research 
will further lead to novel targets for wide-ranging 
clinical regimens aimed at controlling female repro-
duction,  steroidogenesis and endocrine tumorigenesis.
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